<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984148</url>
  </required_header>
  <id_info>
    <org_study_id>GDREC2019152H</org_study_id>
    <nct_id>NCT04984148</nct_id>
  </id_info>
  <brief_title>Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC</brief_title>
  <official_title>Construction of CT Radiomics Model to Assess PD-L1 Status and Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Consolidation immunotherapy of immune checkpoint inhibitor (ICI) following chemoradiotherapy&#xD;
      (CRT) is the current standard of care for patients with unresectable locally advanced&#xD;
      non-small cell lung cancer (NSCLC) as it improves both progression-free survival and overall&#xD;
      survival. However, a substantial proportion of patients still experience disease recurrence&#xD;
      despite consolidation ICI. It is important for personalized treatment to predict the efficacy&#xD;
      of consolidation ICI. PD-L1 expression is used as a predictive biomarker for ICI response and&#xD;
      efficacy in advanced NSCLC, but its role in patients with stage III disease is unclear. One&#xD;
      important reason is PD-L1 testing performed on pre-CRT tissue may not reflect changes in&#xD;
      PD-L1 expression after CRT. CT-based radiomics approaches have been successfully applied to&#xD;
      generate imaging biomarkers as decision support tools for clinical practice. The hypothesis&#xD;
      of this study is that CT radiomics model can assess PD-L1 status after CRT and predict the&#xD;
      efficacy of CRT combined with ICI in unresectable locally advanced NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational longitudinal prospective study.&#xD;
&#xD;
      CT scan is performed before radiotherapy, during radiotherapy and at the end of radiotherapy&#xD;
      in patients with unresectable locally advanced NSCLC who undergo CRT. Radiomic features were&#xD;
      extracted from CT images and baseline PD-L1 expression is assessed. CT-based radiomics models&#xD;
      is developed to assess PD-L1 expression and predict the efficacy of ICI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The association of CT radiomics features with PD-L1 expression of the tumor</measure>
    <time_frame>12 weeks</time_frame>
    <description>To construct a radiomics model for predicting PD-L1 expression after chemoradiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between CT radiomics model and progression-free survival of chemoradiotherapy followed by ICI</measure>
    <time_frame>From date of inclusion to the trial until the date of first documented iRECIST progression or date of death from any cause, assessed up to 5 years</time_frame>
    <description>To construct CT radiomics model for evaluating progression-free survival in patients undergo chemoradiotherapy followed by ICI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between CT radiomics model and overall survival of chemoradiotherapy followed by ICI</measure>
    <time_frame>From date of inclusion to the trial until the date of death from any cause, assessed up to 5 years</time_frame>
    <description>to assess the association between CT radiomics features and overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between CT radiomics model and ICI related pneumonitis</measure>
    <time_frame>5 years</time_frame>
    <description>To develop CT radiomics signatures for predicting ICI related pneumonitis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Stage III Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Trial cohort：Chemoradiotherapy followed by immunotherapy</arm_group_label>
    <description>Contrast-enhanced thoracic CT: before, during and after radiotherapy&#xD;
Radiomics&#xD;
PD-L1 testing (Histological analysis of biopsy)&#xD;
Molecular Markers (Histological analysis of biopsy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT</intervention_name>
    <description>Contrast-enhanced thoracic computed tomography</description>
    <arm_group_label>Trial cohort：Chemoradiotherapy followed by immunotherapy</arm_group_label>
    <other_name>Radiomics</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with stage III NSCLC undergo radical intervention.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological proven non-small cell lung cancer&#xD;
&#xD;
          -  Unresectable stage III according to American Joint Committee of Cancer stage (the&#xD;
             eighth edition)&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous thoracic radiotherapy&#xD;
&#xD;
          -  Palliative treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yi Pan</last_name>
    <phone>+862083827812</phone>
    <email>panyiff011@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Pan, Dr.</last_name>
      <phone>+86-020-83827812</phone>
      <email>panyiff01@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 25, 2021</study_first_submitted>
  <study_first_submitted_qc>July 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>YI PAN</investigator_full_name>
    <investigator_title>Head of the Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>radiomics</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

